Scribe Therapeutics Inc. (NASDAQ:SCTX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Scribe Therapeutics Inc. (NASDAQ:SCTX) have earned a consensus rating of “Moderate Buy” from the five brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $51.75.

SCTX has been the subject of a number of recent research reports. Wall Street Zen upgraded Scribe Therapeutics to a “hold” rating in a research report on Saturday, August 1st. Zacks Research upgraded Scribe Therapeutics to a “hold” rating in a report on Tuesday. Guggenheim initiated coverage on Scribe Therapeutics in a research report on Tuesday, August 18th. They set a “buy” rating and a $50.00 target price on the stock. Leerink Partners started coverage on Scribe Therapeutics in a report on Tuesday, August 18th. They set an “outperform” rating and a $37.00 target price for the company. Finally, HC Wainwright initiated coverage on Scribe Therapeutics in a research note on Monday. They issued a “buy” rating and a $60.00 price target on the stock.

Trending Headlines about Scribe Therapeutics

Here are the key news stories impacting Scribe Therapeutics this week:

• Positive Sentiment: Quarterly loss beat expectations: Scribe reported a second-quarter 2026 loss of $3.84 per share, significantly narrower than the $6.20 loss analysts expected. The earnings surprise may have improved sentiment toward the clinical-stage biotechnology company. Scribe Therapeutics earnings press release
• Positive Sentiment: Pipeline advanced into human testing: The company initiated the first-in-human Phase 1 trial of STX-1150, an ultra-long-acting LDL-cholesterol-lowering therapy using its ELXR epigenetic silencing technology. The treatment is designed to avoid permanent genetic changes, potentially strengthening Scribe’s cardiovascular disease pipeline. Scribe Therapeutics second-quarter results and corporate highlights
• Positive Sentiment: Non-dilutive support and financing improved runway: Scribe received more than $25 million from the California Institute for Regenerative Medicine to advance STX-1200 and STX-1400. In addition, its upsized IPO, including the underwriters’ full option exercise, and a private placement to Sanofi generated approximately $155.5 million in gross proceeds. Management said available funding should support operations into the first half of 2029. Scribe Therapeutics financing and financial results
• Positive Sentiment: Analyst coverage was bullish: HC Wainwright began coverage with a “Buy” rating and a $60 price target, well above the stock’s recent trading level. The firm projects continued losses but expects quarterly losses to narrow after 2026.
• Neutral Sentiment: Management also announced participation in upcoming investor conferences, which could provide additional visibility for Scribe’s technology and clinical programs but does not itself change the company’s fundamentals. Scribe Therapeutics investor conference announcement
• Negative Sentiment: Scribe remains unprofitable, with HC Wainwright forecasting a $6.72 per-share loss for fiscal 2026 and a $4.90 loss for fiscal 2027. Continued clinical spending and the recently issued equity could also create ongoing dilution and volatility risks.

Insider Activity

In other news, Director Carl L. Gordon acquired 1,000,000 shares of the stock in a transaction on Monday, July 27th. The shares were purchased at an average cost of $15.00 per share, for a total transaction of $15,000,000.00. Following the transaction, the director owned 1,348,825 shares in the company, valued at approximately $20,232,375. This trade represents a 286.68% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Behzad Aghazadeh bought 7,905 shares of Scribe Therapeutics stock in a transaction dated Tuesday, July 28th. The stock was acquired at an average price of $18.25 per share, with a total value of $144,266.25. Following the acquisition, the director directly owned 3,088,888 shares of the company’s stock, valued at approximately $56,372,206. This represents a 0.26% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 3,727,237 shares of company stock worth $56,291,746 over the last three months.

Scribe Therapeutics Stock Performance

SCTX stock opened at $30.90 on Thursday. Scribe Therapeutics has a 12 month low of $17.31 and a 12 month high of $39.60.

Scribe Therapeutics (NASDAQ:SCTX) last issued its earnings results on Wednesday, September 2nd. The company reported ($3.84) earnings per share for the quarter, topping analysts’ consensus estimates of ($6.20) by $2.36. On average, sell-side analysts expect that Scribe Therapeutics will post -6.72 EPS for the current fiscal year.

About Scribe Therapeutics

Scribe Therapeutics Inc is a clinical-stage biotechnology company engineering CRISPR-based technologies into purpose-built in vivo genetic medicines designed to become standard of care treatments for patients suffering from highly prevalent diseases, starting with cardiometabolic disease. Scribe Therapeutics Inc is based in ALAMEDA, Calif.